colorectal cancer liver metastases
Conditions
Interventions
Group 1:D-TACE + Regorafenib
Group 2:Oral antiangiogenic drugs
Sponsors
Zhongshan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with liver metastases from colorectal cancer with clear pathology; 2. No obstructive jaundice; 3. Voluntary use of anti-angiogenic drugs as third-line therapy; 4. Patients voluntarily participate in the study and sign the informed consent; 5. Aged over 18 years, and less than 80 years; gender is not limited; 6. There are evaluable lesions according to RECIST criteria.
Exclusion criteria
Exclusion criteria: 1. Patients who cannot be followed up as required by the study; 2. Patients without independent decision-making ability or mental illness; 3. Patients who are being treated with other chemotherapy drugs and targeted drugs; 4. Patients with serious heart, brain, liver and kidney system diseases; 5. The expected survival time is less than 3 months; 6. Those who are allergic or intolerant to the use of anti-angiogenic drugs and drug-eluting microspheres; 7. The use of anti-angiogenic drugs and drug-eluting microspheres is contraindicated.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival;Objective Response Rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactZhou Bo
Zhongshan Hospital Affiliated to Fudan University
Outcome results
None listed